Dynamic Technology Lab Private Ltd bought a new position in shares of Vericel Co. (NASDAQ:VCEL – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 21,544 shares of the biotechnology company’s stock, valued at approximately $910,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Vericel by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock valued at $177,567,000 after purchasing an additional 39,349 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Vericel by 1.7% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 2,075,730 shares of the biotechnology company’s stock worth $87,700,000 after purchasing an additional 34,360 shares in the last quarter. Congress Asset Management Co. raised its holdings in Vericel by 37.4% during the 3rd quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company’s stock worth $54,575,000 after buying an additional 351,550 shares during the period. Geneva Capital Management LLC lifted its stake in Vericel by 61.4% in the third quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock valued at $46,660,000 after buying an additional 420,078 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Vericel by 4.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company’s stock valued at $45,590,000 after buying an additional 47,108 shares during the period.
Vericel Stock Down 1.7 %
NASDAQ:VCEL opened at $57.76 on Thursday. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 962.83 and a beta of 1.66. Vericel Co. has a twelve month low of $32.31 and a twelve month high of $61.49. The stock’s 50 day moving average price is $46.92 and its two-hundred day moving average price is $47.22.
Analyst Ratings Changes
A number of equities research analysts recently commented on VCEL shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. BTIG Research lifted their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday. TD Cowen upped their price target on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Stephens lifted their price objective on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $59.71.
Get Our Latest Stock Report on VCEL
Insider Activity at Vericel
In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. The trade was a 7.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the sale, the director now owns 11,000 shares of the company’s stock, valued at approximately $443,850. This represents a 34.65 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 31,666 shares of company stock worth $1,350,764. Insiders own 7.20% of the company’s stock.
Vericel Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Recommended Stories
- Five stocks we like better than Vericel
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is the Shanghai Stock Exchange Composite Index?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Why Are Stock Sectors Important to Successful Investing?
- 2 Generic Drug Stocks Ready to Surge in 2025
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Co. (NASDAQ:VCEL – Free Report).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.